Low-dose colchicine for the prevention of cardiovascular events after percutaneous coronary intervention: Rationale and design of the COL BE PCI trial

• Published in: The American heart journal Vol. 278; pp. 61 - 71
• Main Authors: De Cock, Emmanuel, Kautbally, Shakeel, Timmermans, Frank, Bogaerts, Kris, Hanet, Claude, Desmet, Walter, Gurné, Olivier, Vranckx, Pascal, Hiltrop, Nick, Dujardin, Karl, Vanduynhoven, Philippe, Vermeersch, Paul, Pirlet, Charles, Hermans, Kurt, Van Reet, Bert, Ferdinande, Bert, Aminian, Adel, Dewilde, Willem, Guédès, Antoine, Simon, François, De Roeck, Frederic, De Vroey, Frédéric, Jukema, J. Wouter, Sinnaeve, Peter, Buysschaert, Ian
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.12.2024; Elsevier Limited
• Subjects: Angina pectoris; Angioplasty; Anti-inflammatory agents; Arteriosclerosis; At risk populations; Atherosclerosis; Cardiovascular disease; Cardiovascular diseases; Cerebral infarction; Colchicine; Compliance; Coronary artery disease; Coronary vessels; Disease prevention; Drug dosages; Effectiveness; Heart attacks; Heart diseases; Inflammation; Laboratories; Meta-analysis; Myocardial infarction; Pathogenesis; Patients; Performance evaluation; Prevention; Questionnaires; Randomization; Stroke; Thrombosis; Vein & artery diseases; ACS; CCS; OD; PHQ-2; PCI; hsCRP; EQ-5D-5L; SMART; SAQ-7

Patients with coronary artery disease (CAD) remain vulnerable to future major atherosclerotic events after revascularization, despite effective secondary prevention strategies. Inflammation plays a central role in the pathogenesis of CAD and recurrent events. To date, there is no specific anti-infla...